Key Highlights
- These 10 stocks could mint the next wave of millionaires › On Tuesday, William Guyer, the chief development officer of Corcept Therapeutics (NASDAQ:CORT), exercised and immediately sold 20,000 shares through open-market transactions totaling approximately $703,656, according to an SEC Form 4 filing.
- Transaction summary Metric Value Shares sold (direct) 20,000 Transaction value $703,656 Post-transaction shares (direct) 1,235 Post-transaction value (direct ownership) $44,188.30 Key questions What is the derivative context of this transaction?This event involved the exercise of 20,000 stock options immediately followed by sale of the resulting common shares on the open market, with no indirect vehicles or gifting components.
- How did this transaction affect William Guyer's direct ownership?Direct common stock holdings declined from 21,235 shares to 1,235 shares, a reduction of 94.18% of his direct equity stake; however, he also reported holding stock options underlying 250,000 shares after the transaction.
- What is the remaining equity exposure after this transaction?After this sale, Guyer retains 1,235 directly held shares valued at approximately $44,188.
- Company overview Metric Value Price (as of market close Tuesday) $35.18 Market capitalization $3.94 billion Revenue (TTM) $741.17 million Net income (TTM) $106.11 million * 1-year performance is calculated using Tuesday as the reference date.
